0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV-52.67%PremiumOct 18, 2024Expiry Date0.35Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.46Leverage Ratio--Theta--Rho--Eff Leverage--Vega
X4 Pharmaceuticals Stock Discussion
The proposed sale was for 1700 dollars. Seems a little silly to risk negative signals right now with such a small amount, especially with the week we just had.
I've been staying away from pennies because of their risk. You can really make good money, but it can also really hurt with loss.
I am gonna test my learning HARD here with X4. I found them while digging around in portfolios of some of the more well known investors with +10% or more annual returns. I had already had them on my watch list from a previous surge.
Their most recent earnings look really good and their books check out. More research...
Xolremdi sales report next month.
holy shit
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
X4 Pharmaceuticals (Nasdaq: XFOR) will host a virtual investor event on June 27, 2024, at 8:00 AM ET to present new interim results from a Phase 2 clinical trial on mavorixafor for treating chronic neutropenia (CN).
The webcast will showcase hematological data from at least 15 participants, treated either wi...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
No comment yet